Evidence map›Paper›PMID 37999115›Full record

ArticleCurrent oncology (Toronto, Ont.)2023

A Population Description of Young Women with Breast Cancer in Newfoundland and Labrador.

Meghan Mahoney, Saranga Sriranganathan, Jeff Dowden, Melanie Seal

Abstract read
In one paragraph

Article in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Personalised graded psychological intervention on negative emotion and quality of life in patients with breast cancer.Technology and health care : official journal of the European Society for Engineering and Medicine · 2024
    Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Meghan MahoneyDiscipline of Oncology, St. John's, NL A1B 3V6, Canada.
Saranga SriranganathanFaculty of Medicine, Memorial University, St. John's, NL A1B 3V6, Canada.
Jeff DowdenCancer Care Program, Newfoundland & Labrador Health Services (NLHS), St. John's, NL A1B 3V6, Canada.
Melanie SealDiscipline of Oncology, St. John's, NL A1B 3V6, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It has been well established in the literature that young women tend to carry more aggressive subtypes of breast cancer than their older-aged counterparts. The objective of this study was to describe the characteristics and outcomes of young women with breast cancer. In this retrospective analysis, data were collected for women under the age of 40 years who were diagnosed with breast cancer between 2008 and 2018 in the province of Newfoundland and Labrador. Specifically, data were collected on demographics, staging, pathological characteristics, treatment, and survival outcomes for young women with this disease. Results demonstrate that most of these women were diagnosed between the age of 35 and 39 years (91.2%). Most women presented with early-stage disease (stage I and II-66.4%), while 24% were stage III and 9.6% presented with stage IV metastatic disease. The prevalence of hormone-receptor-positive disease represented 41.9% of the cohort, with triple-negative and HER2+ measuring 27.7% and 30.4%, respectively. Five-year disease-free survival was 80.5% and overall survival was 82.7%. These findings provoke discussion regarding the intersecting roles of genetics, environment, and lifestyle in a region with some of the highest rates of malignancy in the country.

Indexed as

Breast NeoplasmsAdultErb-b2 Receptor Tyrosine KinasesFemaleHumansNewfoundland and LabradorPrognosisRetrospective StudiesErb-b2 Receptor Tyrosine Kinasesbreastcancerdescriptionpopulationsubtypesurvivalwomen cohortyoung

Identifiers

PMID37999115
PMCPMC10670738

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.